01—Abstract
Summary
Summary of the 10-K/A filed March 3, 2008. Cited figures are marked; the original filing is the authoritative source.
This filing for Stryker Corporation (SYK) pertains to its 2007 annual report, specifically an amendment (10-K/A) filed on March 3, 2008.
The filing primarily incorporates by reference information from the company's 2008 proxy statement regarding its directors and corporate governance. It also provides details on the company's executive officers as of January 31, 2008, including their roles, tenure, and prior experience. Investors can gain insight into the leadership team's background, which can be a crucial factor in assessing management's capabilities and strategic direction.
The report highlights the established corporate governance framework, with key documents such as Corporate Governance Guidelines, committee charters (Audit, Governance and Nominating, Compensation), and the Code of Ethics readily available on the company's website and upon written request. This emphasis on transparency and structured governance is a positive signal for investors concerned with ethical business practices and oversight. The filing also lists the certifications required by Rule 13a-14(a) for the Principal Executive Officer and Principal Financial Officer, underscoring compliance with regulatory standards.
02—Key points
Key Highlights
- The filing incorporates key corporate governance information, including details on directors and committee structures, from the company's 2008 proxy statement.
- Biographical information and tenure are provided for Stryker's executive officers, offering insight into the leadership team's experience.
- Stryker's Corporate Governance Guidelines, committee charters, and Code of Ethics are publicly accessible and available upon request, signaling a commitment to transparency.
- The report includes certifications from the Principal Executive Officer and Principal Financial Officer, demonstrating adherence to regulatory requirements.
- Executive leadership roles have seen some recent appointments or shifts, such as the new President, International and Group President, Stryker Biotech, Osteosynthesis and Development, as of January 2008.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2007, Stryker Corp kept $0.17.
- Revenue$6.00B100.0%
- Cost of revenue−$1.87B31.1%
- Gross profit$4.14B68.9%
- Operating costs−$2.83B47.1%
- Operating income$1.31B21.8%
- Interest, other & tax−$289.9M4.8%
- Net income$1.02B17.0%
Where FY2007 revenue went
$6.00B- SG&A: $2.39B, 40% of revenue
- Cost of revenue: $1.87B, 31% of revenue
- Net income: $1.02B, 17% of revenue
- R&D: $375.3M, 6.3% of revenue
- Other operating costs: $61.2M, 1.0% of revenue
- Interest, other & tax: $289.9M, 4.8% of revenue
Kept 17% as net incomeOther operating costs $61.2M · 1.0%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-K/AFY2007filed March 3, 2008Financial Statements
05—Questions
Frequently Asked Questions
Where can I find detailed financial performance information for Stryker Corporation for the 2007 fiscal year?
This filing is an amendment to the 10-K and primarily focuses on corporate governance and executive officers. Detailed financial statements and performance metrics for the 2007 fiscal year would typically be found in the original 10-K filing for that period, which would include the company's Consolidated Statements of Operations, Balance Sheets, Cash Flows, and related notes.
What are the key corporate governance policies and practices at Stryker as of early 2008?
As of early 2008, Stryker had established Corporate Governance Guidelines, specific charters for its Audit Committee, Governance and Nominating Committee, and Compensation Committee, as well as a Code of Ethics applicable to its principal officers. These documents are available on the company's website and upon written request, indicating a structured approach to governance and oversight.
Who are the key executive officers at Stryker Corporation and what are their backgrounds?
The filing lists several key executive officers, including Stephen P. MacMillan (CEO), Dean H. Bergy (VP and CFO), Andrew G. Fox-Smith (President, International), Curtis E. Hall (VP and General Counsel), Stephen Si Johnson (VP, Group President, MedSurg), James E. Kemler (VP, Group President, Stryker Biotech, Osteosynthesis and Development), and Michael W. Rude (VP, Human Resources). Their backgrounds include extensive experience within Stryker and prior roles at other major corporations like Pharmacia, Johnson & Johnson, Pfizer, Ernst & Young, and Baxter International.
Does this filing provide information about potential risks or uncertainties facing Stryker?
This specific excerpt of the 10-K/A filing does not detail risks and uncertainties. Those discussions are typically found in a dedicated 'Risk Factors' section within the full 10-K report, providing a comprehensive overview of potential challenges to the company's business operations and financial performance.
06—Continue